Readings Flashcards
(83 cards)
In what year was OSA first described in the medical literature?
1965
What features regarding jaw movement make an oral appliance less likely to cause adverse events and increase patient compliance?
Allows vertical opening.
Allows lateral movement.
In what two ways do oral appliances maintain patency of the airway?
By increasing its dimensions and decreasing its collapsibility.
(Chest 2007;132;693-699)
How do oral appliances (physically) enlarge the airway and/or reduce its collapsibility?
This is mediated by anatomical changes that occur by advancement of the tongue and jaw. The activation of upper airway neuromuscular reflexes may also be relevant. These changes are not uniformly seen in all patients and this may explain differences in treatment outcomes. (Chest 2007;132;693-699)
What is a “complete response” and a “partial response” in treatment of OSA?
Complete: AHI 49%, but final AHI >5.
Chest 2007;132;693-699
According to a 2007 Chest article, what percentage of OSA patients can expect a clinically important response to OA therapy?
About 2/3 - 35% to 40% complete response, 25% partial response, which leaves 35% to 40% failures. (Chest 2007;132;693-699)
How does OA therapy compare to CPAP in terms of PSG, AHI, subjective and objective measures of sleepiness, and compliance?
PSG & AHI: OA is less
S/O sleepiness: Equal
Compliance: higher
(Chest 2007;132;693-699)
Why is higher compliance relevant even when the treatment is less effective?
The extent to which a treatment alleviates a health risk associated with a disease in clinical practice is a function of its efficacy and treatment adherence. The greater acceptance by patients of OA could result in greater treatment adherence and provide equivalent clinical effectiveness. (Chest 2007;132;693-699)
What was the 1 year treatment adherence rate of OA therapy compared to that of CPAP as reported in a 2007 Chest article?
77% OA (6.8 hours per night) vs. 46% CPAP (>4 hrs/night for 70% of nights). (Chest 2007;132;693-699)
Does OA therapy reduce BP levels in OSA patients?
Yes, early indications are that OA therapy may have a positive impact (2-4 mm Hg at 1- and 3-month checks in 2 studies). (Chest 2007;132;693-699)
OA vs. CPAP: Improvement of snoring
Moderate benefit vs. large benefit. (Chest 2007;132;693-699)
Comparison of OA to CPAP: improvement in AHI
OA: Moderate benefit CPAP: Large benefit
Chest 2007;132;693-699
Compare benefit of CPAP to OA: SpO2
OA: Mod CPAP: Large
Chest 2007;132;693-699
Compare benefit of OA to CPAP: sleep fragmentation
OA: mod CPAP: large
Chest 2007;132;693-699
Compare OA to CPAP: sleep architecture
OA: small CPAP: mod
Chest 2007;132;693-699
Compare OA to CPAP: S/O measures of daytime sleepiness
OA: mod CPAP: mod
Chest 2007;132;693-699
Compare OA and CPAP: reduction in BP
OA: mod CPAP: mod
Chest 2007;132;693-699
Compare benefits of OA to CPAP: neuropsychological function
OA: small CPAP: small
Chest 2007;132;693-699
Compare benefits of OA and CPAP: quality of life
OA: small CPAP: small
Chest 2007;132;693-699
Compare benefits of OA and CPAP: reduction in motor vehicle accident risk
OA: unknown CPAP: small
Chest 2007;132;693-699
What are the demographic, anthropomorphic, and physiologic predictors of a favorable response to OA therapy?
Remember, it is not currently possible to identify with certainty which patients will respond in clinical practice. Female, lower age, lower BMI, lower neck circumference, lower baseline AHI, supine-dependent OSA, primary oropharyngeal collapse during sleep.(Chest 2007;132;693-699)
What are the cephalometric predictors of a favorable response to OA therapy?
Remember, it is not currently possible to identify with certainty which patients will respond in clinical practice. Shorter soft palate, larger retropalatal airway space, decreased distance between hyoid and mandibular plane, narrower angle from sella to nasion to supramentale point, wider angle from the sella to the nasion to the subspinale point. (Chest 2007;132;693-699)
What are the upper airway predictors of a favorable response to OA therapy?
Remember, it is not currently possible to identify with certainty which patients will respond in clinical practice. Airway patency on MRI during Muller maneuver following mandibular advancement, improvement in airway patency with mandibular advancement during drug-induced “sleep” nasopharyngoscopy. (Chest 2007;132;693-699)
What are the key short-term adverse effects reported with OA therapy?
Excessive salivation, mouth dryness, tooth pain, gum irritation, headaches, TMJ discomfort.
These tend to be self-limiting but must be addressed early to increase the likelihood of treatment adherence. (Chest 2007;132;693-699)